Long-Acting Antiretrovirals: Where Are We now?
- 16 March 2017
- journal article
- review article
- Published by Springer Nature in Current HIV/AIDS Reports
- Vol. 14 (2) , 63-71
Abstract
Purpose of Review Current HIV treatment options require daily use of combination antiretroviral drugs. Many persons living with HIV experience treatment fatigue and suboptimal adherence as a result. Long-acting antiretroviral drugs are being developed to expand options for HIV treatment. Here, we review the agents in development, and evaluate data from recent clinical trials. In addition, we anticipate challenges to successful widespread use of long-acting antiretrovirals. Recent Findings Parenteral nanosuspensions of cabotegravir and rilpivirine, and dapivirine vaginal ring are the farthest in clinical development. Long-acting modalities in earlier development stages employ drug-loaded implants, microparticles, or targeted mutagenesis, among other innovations. Summary Long-acting antiretroviral drugs promise new options for HIV prevention and treatment, and ways to address poor adherence and treatment fatigue. Further studies will identify the long-acting agents or combinations that are suitable for routine use. Creative solutions will be needed for anticipated implementation challenges.Keywords
Funding Information
- ViiV Healthcare
This publication has 43 references indexed in Scilit:
- Cabotegravir long acting injection protects macaques against intravenous challenge with SIVmac251AIDS, 2017
- Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessmentThe Lancet HIV, 2016
- Safety, Acceptability and Adherence of Dapivirine Vaginal Ring in a Microbicide Clinical Trial Conducted in Multiple Countries in Sub-Saharan AfricaPLOS ONE, 2016
- Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trialThe Lancet Infectious Diseases, 2015
- Formulation and pharmacology of long-acting rilpivirineCurrent Opinion in HIV and AIDS, 2015
- Safety, tolerability and pharmacokinetics of rilpivirine following administration of a long‐acting formulation in healthy volunteersHIV Medicine, 2015
- Level of Adherence and HIV RNA Suppression in the Current Era of Highly Active Antiretroviral Therapy (HAART)AIDS and Behavior, 2014
- Cause-Specific Life Expectancies After 35 Years of Age for Human Immunodeficiency Syndrome-Infected and Human Immunodeficiency Syndrome-Negative Individuals Followed Simultaneously in Long-term Cohort Studies, 1984–2008American Journal of Epidemiology, 2013
- The Effects of Housing Status on Health-Related Outcomes in People living with HIV: A Systematic Review of the LiteratureAIDS and Behavior, 2007
- Social Support, Disclosure, and Use of Antiretroviral TherapyAIDS and Behavior, 2006